CPIX vs. ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, and JAZZ
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceuticals" industry.
Cumberland Pharmaceuticals vs.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Cumberland Pharmaceuticals has higher revenue and earnings than Assembly Biosciences.
15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 43.3% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Assembly Biosciences has a consensus target price of $35.00, suggesting a potential upside of 137.29%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.
Cumberland Pharmaceuticals has a net margin of -29.54% compared to Assembly Biosciences' net margin of -144.05%. Cumberland Pharmaceuticals' return on equity of -9.50% beat Assembly Biosciences' return on equity.
In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 1 mentions for Cumberland Pharmaceuticals and 0 mentions for Assembly Biosciences. Cumberland Pharmaceuticals' average media sentiment score of 0.00 beat Assembly Biosciences' score of -0.55 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.
Assembly Biosciences received 56 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 58.84% of users gave Assembly Biosciences an outperform vote while only 41.74% of users gave Cumberland Pharmaceuticals an outperform vote.
Cumberland Pharmaceuticals has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Summary
Cumberland Pharmaceuticals and Assembly Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CPIX) was last updated on 1/22/2025 by MarketBeat.com Staff
